Technology evaluation: HspE7, StressGen Biotechnologies Corp

Current Opinion in Molecular Therapeutics

Volumn 3, Issue 4, 2001, Pages 413-417

  Hunt, S ^a  

^a NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 65; HEAT SHOCK PROTEIN E7; HYBRID PROTEIN; ONCOCINE HPV 16; RECOMBINANT PROTEIN; SGN 00101; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANUS DISEASE; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONDYLOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG SYNTHESIS; DYSPLASIA; FEMALE; HUMAN; IMMUNIZATION; MALE; MOUSE; MYCOBACTERIUM BOVIS; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; SIDE EFFECT; UTERINE CERVIX DYSPLASIA; UTERINE CERVIX TUMOR; WART VIRUS;

BACTERIAL PROTEINS; CHAPERONINS; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RECOMBINANT FUSION PROTEINS; TUMOR VIRUS INFECTIONS; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 0034879521     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Tests demonstrate inhibition of cancer growth by StressGen's proprietary vaccines
2. StressGen moves new treatment for cervical cancer into development
3. StressGen's lead product eradicates tumors in preclinical models of cervical cancer
4. StressGen reports second quarter results
5. StressGen initiates phase I clinical trials of HspE7 for cervical dysplasia
6. StressGen initiates second clinical trial for HspE7 in healthy volunteers
7. StressGen completes phase I trial of lead product in healthy volunteers
8. USA's National Cancer Institute to support new clinical trial of Stress Gen's lead product - HspE7 to be used in HIV+ patients with anal dysplasia
9. StressGen initiates phase II clinical trial of its lead compound HspE7: Efficacy of HspE7 in high-grade anal dysplasia to be tested
10. StressGen signs clinical trials agreement with USA's National Cancer Institute for HspE7 - Additional trials to be conducted in HPV-related diseases
11. Whitehead Institute /MIT study suggests StressGen's stress proteins may play a key role in treating immunocompromised populations
12. StressGen Biotechnologies announces initiation of phase II study with HspE7
13. StressGen reports fusion protein drug for human papillomavirus demonstrated positive immune responses and is well tolerated in phase I study - Data presented at Annual Meeting of American Society of Clinical Oncology
14. Antigen specific cell mediated immunity in phase I dose-escalation trial of single doses of HspE7 in healthy volunteers
15. Positive clinical data advances StressGen's HspE7 to phase III in anal dysplasia - HspE7 clinical program expanded to include genital warts
16. StressGen presents positive clinical data at 18th International Papillomavirus Conference: HspE7: A novel heat shock protein fusion for HPV-related diseases
17. StressGen reports data on recombinant fusion protein HspE7 mechanism of action Clin Exp Immuno paper also highlights potential novel therapeutic approach for immunocompromised patient population
18. StressGen Biotechnologies initiates HspE7 phase II trial in cervical cancer
19. StressGen initiates HspE7 phase III trial in HPV-related anal dysplasia: CDC reports HPV second only to HIV in US STD related healthcare costs
20. StressGen scientists and key MIT collaborators present at an International Symposium on Heat Shock Proteins in Biology and Medicine: Data reinforces utility of heat shock protein fusions as platform for immunotherapeutics
21. StressGen announces ruling in European patent opposition proceedings
22. StressGen initiates phase II genital warts trial - Trial expands broad-spectrum activity of HspE7 in HPV-related diseases
23. Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV 16 E7
24. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumor by administration of fusion protein comprising Mycobacterium bovis bacilli Calmette-Guerin (BCG) hsp65 and HPV16 E7